CYCN

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious central nervous system and peripheral diseases. The company's lead programs target soluble guanylate cyclase (sGC), an enzyme involved in multiple disease pathways. Cyclerion's pipeline includes product candidates for mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), serious CNS diseases, and other conditions. The company leverages its sGC platform to develop novel therapeutic approaches for diseases with significant unmet medical needs.